Identifying Optimal Serum 1,3-β-D-Glucan Cut-off for Diagnosing Pneumocystis Jirovecii Pneumonia in Non-HIV Patients in the Intensive Care Unit

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Sep 20

PMID 39304817

Authors

Yuan-Yuan Li

Yan Chen

Shan Li

Run Dong

Qi-Wen Yang

Jin-Min Peng

Bin Du

Affiliations

Soon will be listed here.

Abstract

Background: Serum (1,3)-β-D-glucan (BDG) detection for diagnosis of Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus (HIV) immunocompromised patients lacks intensive care unit (ICU)-specific data. We aimed to assess its performance and determine the optimal cutoff for PJP in ICU population.

Methods: This retrospective study included critically ill non-HIV immunocompromised patients admitted to a medical ICU with suspected pneumonia, undergoing simultaneous microbiological testing for P. jirovecii on lower respiratory tract specimens and serum BDG. Confounders affecting BDG positivity were explored by multivariable logistic regression. Optimal cut-offs were derived from Youden's index for the entire cohort and subgroups stratified by confounders. Diagnostic performance of serum BDG was estimated at different cutoffs.

Results: Of 400 patients included, 42% were diagnosed with PJP and 58.3% had positive serum BDG. Serum BDG's area under the receiver operating characteristic curve was 0.90 (0.87-0.93). At manufacturer's 150 pg/ml cut-off, serum BDG had high sensitivity and negative predictive value (94%), but low specificity and positive predictive value (67%). Confounders associated with a positive serum BDG in PJP diagnosis included IVIG infusion within 3 days (odds ratio [OR] 9.24; 95% confidence interval [CI] 4.09-20.88, p < 0.001), other invasive fungal infections (OR 4.46; 95% CI 2.10-9.49, p < 0.001) and gram-negative bacteremia (OR 29.02; 95% CI 9.03-93.23, p < 0.001). The application of optimal BDG cut-off values determined by Youden's index (252 pg/ml, 390 pg/ml, and 202 pg/ml) specific for all patients and subgroups with or without confounders improved the specificity (79%, 74%, and 88%) and corresponding PPV (75%, 65%, and 85%), while maintaining reasonable sensitivity and NPV.

Conclusions: Tailoring serum BDG cutoff specific to PJP and incorporating consideration of confounders could enhance serum BDG's diagnostic performance in the ICU settings.

References

Desmet S, Van Wijngaerden E, Maertens J, Verhaegen J, Verbeken E, De Munter P . Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. 2009; 47(12):3871-4. PMC: 2786638. DOI: 10.1128/JCM.01756-09. View

Hsu A, Tamma P, Zhang S . Challenges with Utilizing the 1,3-Beta-d-Glucan and Galactomannan Assays To Diagnose Invasive Mold Infections in Immunocompromised Children. J Clin Microbiol. 2021; 59(9):e0327620. PMC: 8373034. DOI: 10.1128/JCM.03276-20. View

Giacobbe D, Dettori S, Di Pilato V, Asperges E, Ball L, Berti E . Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Crit Care. 2023; 27(1):323. PMC: 10464114. DOI: 10.1186/s13054-023-04608-1. View

Mercier T, Guldentops E, Patteet S, Beuselinck K, Lagrou K, Maertens J . Beta-d-Glucan for Diagnosing Pneumonia: a Direct Comparison between the Wako β-Glucan Assay and the Fungitell Assay. J Clin Microbiol. 2019; 57(6). PMC: 6535610. DOI: 10.1128/JCM.00322-19. View

Metan G, Koc A, Agkus C, Kaynar L, Alp E, Eser B . Can bacteraemia lead to false positive results in 1,3-beta-D-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. Rev Iberoam Micol. 2011; 29(3):169-71. DOI: 10.1016/j.riam.2011.07.003. View

Azoulay E, Guigue N, Darmon M, Mokart D, Lemiale V, Kouatchet A . (1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies. Oncotarget. 2016; 7(16):21484-95. PMC: 5008300. DOI: 10.18632/oncotarget.7471. View

Morjaria S, Frame J, Franco-Garcia A, Geyer A, Kamboj M, Babady N . Clinical Performance of (1,3) Beta-D Glucan for the Diagnosis of Pneumocystis Pneumonia (PCP) in Cancer Patients Tested With PCP Polymerase Chain Reaction. Clin Infect Dis. 2018; 69(8):1303-1309. PMC: 6763633. DOI: 10.1093/cid/ciy1072. View

Szvalb A, Malek A, Jiang Y, Bhatti M, Wurster S, Kontoyiannis D . Serum (1,3)-Beta-d-Glucan has suboptimal performance for the diagnosis of Pneumocystis jirovecii pneumonia in cancer patients and correlates poorly with respiratory burden as measured by quantitative PCR. J Infect. 2020; 81(3):443-451. DOI: 10.1016/j.jinf.2020.07.003. View

Fauchier T, Hasseine L, Gari-Toussaint M, Casanova V, Marty P, Pomares C . Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients. J Clin Microbiol. 2016; 54(6):1487-1495. PMC: 4879311. DOI: 10.1128/JCM.03174-15. View

10.

Mennink-Kersten M, Verweij P . Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am. 2006; 20(3):711-27, viii. DOI: 10.1016/j.idc.2006.06.009. View

11.

Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D . Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003; 10(5):882-5. PMC: 193887. DOI: 10.1128/cdli.10.5.882-885.2003. View

12.

Bassetti M, Azoulay E, Kullberg B, Ruhnke M, Shoham S, Vazquez J . EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. Clin Infect Dis. 2021; 72(Suppl 2):S121-S127. DOI: 10.1093/cid/ciaa1751. View

13.

Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A . Contribution of the (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2007; 46(3):1009-13. PMC: 2268340. DOI: 10.1128/JCM.02091-07. View

14.

Salerno D, Mushatt D, Myers L, Zhuang Y, de la Rua N, Calderon E . Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients. Respir Med. 2014; 108(11):1688-95. PMC: 4297544. DOI: 10.1016/j.rmed.2014.09.017. View

15.

Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge R . Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004; 39(2):199-205. DOI: 10.1086/421944. View

16.

Hammarstrom H, Kondori N, Friman V, Wenneras C . How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J Clin Microbiol Infect Dis. 2015; 34(5):917-25. DOI: 10.1007/s10096-014-2302-9. View

17.

Schmidt J, Lueck C, Ziesing S, Stoll M, Haller H, Gottlieb J . Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care. 2018; 22(1):307. PMC: 6245758. DOI: 10.1186/s13054-018-2221-8. View

18.

Albert O, Toubas D, Strady C, Cousson J, Delmas C, Vernet V . Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis. 2011; 30(11):1453-60. DOI: 10.1007/s10096-011-1244-8. View

19.

Lahmer T, Prazeres da Costa C, Held J, Rasch S, Ehmer U, Schmid R . Usefulness of 1,3 Beta-D-Glucan Detection in non-HIV Immunocompromised Mechanical Ventilated Critically Ill Patients with ARDS and Suspected Pneumocystis jirovecii Pneumonia. Mycopathologia. 2017; 182(7-8):701-708. DOI: 10.1007/s11046-017-0132-x. View

20.

Lu Y, Chen Y, Guo Y, Qin S, Wu C, Wang K . Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: a bivariate meta-analysis. Intern Med. 2011; 50(22):2783-91. DOI: 10.2169/internalmedicine.50.6175. View